ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Total Liabilities & Equity
ADC Therapeutics SA
Total Liabilities & Equity Peer Comparison
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Total Liabilities & Equity
$354.8m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Total Liabilities & Equity
CHf182.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Liabilities & Equity
$2.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Liabilities & Equity
CHf173.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
Idorsia Ltd
SIX:IDIA
|
Total Liabilities & Equity
CHf904.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Liabilities & Equity
CHf82.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Total Liabilities & Equity?
Total Liabilities & Equity
354.8m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Total Liabilities & Equity amounts to 354.8m USD.
What is ADC Therapeutics SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
19%
Over the last year, the Total Liabilities & Equity growth was -33%. The average annual Total Liabilities & Equity growth rates for ADC Therapeutics SA have been -12% over the past three years , 19% over the past five years .